However, metastatic melanoma patients treated with double immune checkpoint inhibition and metastatic NSCLC patients treated with anaplastic lymphoma kinase (ALK)-targeting tyrosine kinase inhibitors (TKIs) are today achieving median OS beyond 3–5 years [16–18]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.